Cargando…

Phase I Clinical Trial of Prostate-Specific Membrane Antigen-Targeting (68)Ga-NGUL PET/CT in Healthy Volunteers and Patients with Prostate Cancer

OBJECTIVE: (68)Ga-NGUL is a novel prostate-specific membrane antigen (PSMA)-targeting tracer based on Glu-Urea-Lys derivatives conjugated to a 1,4,7-triazacyclononane-N, N′, N″-triacetic acid (NOTA) chelator via a thiourea-type short linker. This phase I clinical trial of (68)Ga-NGUL was conducted t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suh, Minseok, Ryoo, Hyun Gee, Kang, Keon Wook, Jeong, Jae Min, Jeong, Chang Wook, Kwak, Cheol, Cheon, Gi Jeong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Radiology 2022
Materias:	Nuclear Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434735/ https://www.ncbi.nlm.nih.gov/pubmed/35762185 http://dx.doi.org/10.3348/kjr.2022.0176

Ejemplares similares

The influence of digital PET/CT on diagnostic certainty and interrater reliability in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer
por: Alberts, Ian, et al.
Publicado: (2021)

Phase 1 Study of No-Carrier Added (177)Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor–Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea
por: Ryoo, Hyun Gee, et al.
Publicado: (2023)

Combined forced diuresis and late acquisition on [(68)Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study
por: Bauckneht, Matteo, et al.
Publicado: (2023)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

Specificity of (68)Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality
por: Sasikumar, Arun
Publicado: (2017)

Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges
por: Oh, So Won, et al.
Publicado: (2018)

Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [(68)Ga]Ga DOTATATE PET-CT
por: Bilen, Mehmet Asim, et al.
Publicado: (2022)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

(68)Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2019)

Re: The role of (68)Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2019)

Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer
por: Kwan, Timothy N., et al.
Publicado: (2021)

Cost-effectiveness of the implementation of [(68)Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging
por: van der Sar, Esmée C. A., et al.
Publicado: (2022)

The use of (68)Ga prostate-specific membrane antigen PET-CT in prostate cancer: diagnostic challenges and therapeutic opportunities
por: Franzese, Elisena, et al.
Publicado: (2021)

Comparison of (68)Ga-PSMA PET/CT with fluoride PET/CT for detection of bone metastatic disease in prostate cancer
por: Regula, Naresh, et al.
Publicado: (2022)

A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer
por: Wang, Guochang, et al.
Publicado: (2023)

The value of (68)Ga-PSMA enhanced PET-CT and MR-PET in patients with biochemical recurrent prostate cancer
por: Rummeny, E, et al.
Publicado: (2015)

Accuracy of (68)Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer
por: Barbosa, Álan Roger Gomes, et al.
Publicado: (2022)

Hybrid imaging with [(68)Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
por: Glemser, P. A., et al.
Publicado: (2022)

(68)Ga-PSMA-PET/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2018)

68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?
por: Witkowska-Patena, Ewa, et al.
Publicado: (2017)

Role of Early PET/CT Imaging with 68Ga-PSMA in Staging and Restaging of Prostate Cancer
por: Barakat, Andrew, et al.
Publicado: (2020)

Superscan Appearance of (68)Ga PSMA PET/CT in a Patient with Refractory Prostate Cancer
por: Koç, Zehra Pınar, et al.
Publicado: (2022)

Von Hippel-Lindau Syndrome: Demonstration of Entire Disease Spectrum with (68)Ga-DOTANOC PET-CT
por: Sharma, Punit, et al.
Publicado: (2014)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Incidental prostate-specific membrane antigen-avid meningioma detected on (68)Ga–prostate-specific membrane antigen PET/CT
por: Jiang, James Yuheng, et al.
Publicado: (2021)

Incidental prostate-specific membrane antigen-avid glioblastoma detected on (68)Ga–prostate-specific membrane antigen PET/CT
por: Jiang, James Yuheng, et al.
Publicado: (2022)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

68Ga-PSMA PET/CT in prostate cancer patients – patterns of disease, benign findings and pitfalls
por: Keidar, Zohar, et al.
Publicado: (2018)

(68)Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients
por: Zang, Shiming, et al.
Publicado: (2017)

68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer
por: Kalinauskaite, Goda, et al.
Publicado: (2020)

The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer
por: Erdoğan, Mehmet, et al.
Publicado: (2020)

Combined Intravenous Urogram and 68Ga-PSMA PET/ CT for Improved Staging and Restaging of Prostate Cancer
por: McBean, Rhiannon, et al.
Publicado: (2020)

Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by (68)Ga-PSMA PET/CT
por: Christensen, Mads T., et al.
Publicado: (2022)

Cancers and Benign Processes on (68) Ga PSMA PET-CT Imaging Other than Prostate Cancer
por: Ozcan, Pinar Pelin, et al.
Publicado: (2022)

(68)Ga-PSMA PET/CT in early relapsed prostate cancer patients after radical therapy
por: Haidar, Mohamad, et al.
Publicado: (2022)

Staging Prostate Cancer with (68)Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?
por: Kesler, Mikhail, et al.
Publicado: (2023)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

Dual-Time Point [(68)Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer
por: Hoffmann, Manuela A., et al.
Publicado: (2020)

Diagnostic Performance of [(18)F]Fluorocholine and [(68)Ga]Ga-PSMA PET/CT in Prostate Cancer: A Comparative Study
por: Paymani, Zeinab, et al.
Publicado: (2020)

DNA Damage in Blood Leukocytes of Prostate Cancer Patients Undergoing PET/CT Examinations with [(68)Ga]Ga-PSMA I&T
por: Schumann, Sarah, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8b3mgchtvujig68mmvgs9afa1n